Total Payments
$809,018
2024 Payments
$61,330
Companies
19
Transactions
498
Medicare Patients
688
Medicare Billing
$157,240
Payment Breakdown by Category
Other$661,988 (81.8%)
Travel$110,735 (13.7%)
Consulting$17,780 (2.2%)
Food & Beverage$10,879 (1.3%)
Research$7,402 (0.9%)
Education$234.62 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $658,738 | 183 | 81.4% |
| Travel and Lodging | $110,735 | 154 | 13.7% |
| Consulting Fee | $17,780 | 11 | 2.2% |
| Food and Beverage | $10,879 | 136 | 1.3% |
| Unspecified | $7,402 | 4 | 0.9% |
| Honoraria | $2,500 | 1 | 0.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $750.00 | 1 | 0.1% |
| Education | $234.62 | 8 | 0.0% |
Payments by Type
General
$801,616
494 transactions
Research
$7,402
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kite Pharma, Inc. | $224,247 | 133 | $0 (2023) |
| Celgene Corporation | $177,751 | 122 | $0 (2022) |
| ABBVIE INC. | $163,579 | 79 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $130,180 | 73 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $46,250 | 25 | $0 (2020) |
| Gilead Sciences, Inc. | $30,863 | 26 | $0 (2018) |
| Seattle Genetics, Inc. | $28,894 | 22 | $0 (2019) |
| Millennium Pharmaceuticals, Inc. | $3,300 | 1 | $0 (2017) |
| Seagen Inc. | $2,020 | 2 | $0 (2021) |
| GENZYME CORPORATION | $1,006 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $61,330 | 32 | ABBVIE INC. ($35,222) |
| 2023 | $123,519 | 63 | E.R. Squibb & Sons, L.L.C. ($46,541) |
| 2022 | $94,527 | 49 | Kite Pharma, Inc. ($48,418) |
| 2021 | $74,467 | 38 | Celgene Corporation ($31,162) |
| 2020 | $52,647 | 34 | AbbVie Inc. ($21,791) |
| 2019 | $174,395 | 105 | Kite Pharma, Inc. ($68,191) |
| 2018 | $134,852 | 111 | Celgene Corporation ($48,985) |
| 2017 | $93,281 | 66 | Celgene Corporation ($45,776) |
All Payment Transactions
498 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,600.00 | General |
| Category: ONCOLOGY | ||||||
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | ABECMA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,176.00 | General |
| Category: Oncology | ||||||
| 12/18/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $1,289.38 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $95.80 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,176.00 | General |
| Category: Hematology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,176.00 | General |
| Category: Hematology | ||||||
| 12/04/2024 | E.R. Squibb & Sons, L.L.C. | ABECMA (Biological) | Travel and Lodging | Cash or cash equivalent | $366.55 | General |
| Category: Oncology | ||||||
| 12/04/2024 | E.R. Squibb & Sons, L.L.C. | ABECMA (Biological) | Food and Beverage | Cash or cash equivalent | $117.64 | General |
| Category: Oncology | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $26.73 | General |
| Category: Hematology | ||||||
| 11/06/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Travel and Lodging | Cash or cash equivalent | $466.38 | General |
| Category: Hematology | ||||||
| 09/24/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $837.49 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $117.51 | General |
| Category: ONCOLOGY | ||||||
| 08/06/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,600.00 | General |
| Category: ONCOLOGY | ||||||
| 08/06/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,600.00 | General |
| 07/31/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,447.00 | General |
| Category: Hematology | ||||||
| 07/30/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,600.00 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | E.R. Squibb & Sons, L.L.C. | ONUREG (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,447.00 | General |
| Category: Oncology | ||||||
| 07/17/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $1,070.10 | General |
| Category: ONCOLOGY | ||||||
| 07/17/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $89.35 | General |
| Category: ONCOLOGY | ||||||
| 07/15/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Travel and Lodging | Cash or cash equivalent | $932.76 | General |
| Category: Hematology | ||||||
| 07/15/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $117.20 | General |
| Category: Hematology | ||||||
| 07/11/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $1,207.04 | General |
| 07/11/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $35.13 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AZA-MDS-006 - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry | Celgene Corporation | $3,048 | 1 |
| Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry (AZA-MDS-006) | Celgene Corporation | $2,866 | 1 |
| AZA-MDS-006 | Celgene Corporation | $1,488 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 178 | 562 | $270,784 | $52,485 |
| 2022 | 6 | 170 | 428 | $209,770 | $38,158 |
| 2021 | 5 | 185 | 476 | $198,309 | $42,522 |
| 2020 | 4 | 155 | 334 | $113,902 | $24,075 |
Total Patients
688
Total Services
1,800
Medicare Billing
$157,240
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 63 | 179 | $125,121 | $20,895 | 16.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 35 | 152 | $59,432 | $15,048 | 25.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 27 | 128 | $34,525 | $8,429 | 24.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 53 | 103 | $51,706 | $8,113 | 15.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 27 | 173 | $66,921 | $14,606 | 21.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 43 | 85 | $58,327 | $9,977 | 17.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 56 | 122 | $59,228 | $9,364 | 15.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 11 | 11 | $9,167 | $1,665 | 18.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 12 | 12 | $7,566 | $1,336 | 17.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 21 | 25 | $8,561 | $1,211 | 14.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 30 | 192 | $65,439 | $16,499 | 25.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 55 | 98 | $55,545 | $11,711 | 21.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 59 | 126 | $54,303 | $10,229 | 18.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 30 | 49 | $14,389 | $2,382 | 16.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 11 | 11 | $8,633 | $1,701 | 19.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 26 | 109 | $35,445 | $9,611 | 27.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 44 | 86 | $30,946 | $5,586 | 18.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 34 | 59 | $27,950 | $5,550 | 19.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 51 | 80 | $19,561 | $3,328 | 17.0% |
About Dr. Mehrad Abedi, M.D
Dr. Mehrad Abedi, M.D is a Specialist healthcare provider based in Sacramento, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1467459222.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mehrad Abedi, M.D has received a total of $809,018 in payments from pharmaceutical and medical device companies, with $61,330 received in 2024. These payments were reported across 498 transactions from 19 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($658,738).
As a Medicare-enrolled provider, Abedi has provided services to 688 Medicare beneficiaries, totaling 1,800 services with total Medicare billing of $157,240. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Sacramento, CA
- Active Since 07/07/2005
- Last Updated 08/30/2019
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1467459222
Products in Payments
- Yescarta (Drug) $219,844
- VENCLEXTA (Drug) $113,235
- Revlimid (Drug) $110,940
- REBLOZYL (Biological) $67,379
- Venclexta (Drug) $43,502
- ONUREG (Drug) $35,767
- NINLARO (Drug) $32,137
- Zydelig (Drug) $27,985
- ADCETRIS (Biological) $27,657
- Pomalyst (Drug) $27,219
- EMPLICITI (Biological) $26,168
- ABECMA (Biological) $8,062
- CC-486 (Drug) $6,331
- Inrebic (Drug) $5,989
- SGN35 (Biological) $3,190
- Tecartus (Drug) $2,400
- Vidaza (Drug) $1,071
- Imbruvica (Drug) $326.87
- Venclexta (Biological) $150.00
- KYMRIAH (Biological) $123.06
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Sacramento
Dr. Jeffrey Gregg, M.d, M.D
Specialist — Payments: $1.2M
Specialist $1.2M
Dr. Nancy Lane, M.d, M.D
Specialist — Payments: $434,011
Specialist $434,011
Dr. Naveen Atray, M.d, M.D
Specialist — Payments: $99,483
Specialist $99,483
David Pai, Md, MD
Specialist — Payments: $37,989
Specialist $37,989
William Cushard, M.d, M.D
Specialist — Payments: $31,555
Specialist $31,555
Dr. Christopher Polage, M.d, M.D
Specialist — Payments: $18,465
Specialist $18,465